Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Macular Edema and Macular Degeneration Market Grown from 2024 to 2025?

In recent times, the market size for macular edema and macular degeneration has experienced robust growth. Projected growth indicates an increase from $9.65 billion in 2024 to $10.43 billion in 2025, evidencing a compound annual growth rate (CAGR) of 8.1%. Various factors contributing to this growth during the historical period include an aging population, higher diabetes prevalence, more awareness and early diagnosis, worldwide initiatives toward eye health, innovative pharmaceutical developments, and increased patient advocacy and support.

What Growth Rate Is Anticipated for the Macular Edema and Macular Degeneration Market in the Coming Years?

In the coming years, robust growth is anticipated in the market size of macular edema and macular degeneration, with projections estimating it will expand to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. Factors contributing to the growth in the predicted period include the application of personalized medicine, heightened awareness in developing markets, emphasis on combination therapies, collaboration with teleophthalmology services, and the impact of the worldwide aging population. Major trends for the forecasted timeframe include breakthroughs in sustained-release drug administration, the inclusion of gene therapies, the emergence of cutting-edge imaging technologies, customized treatment plans focusing on biomarkers, remote monitoring via teleophthalmology, and enhancements in diagnostic artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Who Are the Leading Companies in the Macular Edema and Macular Degeneration Market?

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

What Are the Key Drivers of the Macular Edema and Macular Degeneration Market?

The growth of the macular edema and macular degeneration market is predicted to be fueled by the increasing diabetes population. Diabetes is a persistent health issue defined by elevated levels of glucose in the bloodstream. It impairs ocular blood vessels, leading to macular edema and macular degeneration. For example, The National Health Service (NHS England) reported in June 2024 that there was an 18% rise in identified pre-diabetic individuals in England, from 3,065,825 in 2022 to 3,615,330 in 2023. In addition, there was a nearly 25% rise in cases amongst those under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the escalating diabetes prevalence is spurring the macular edema and macular degeneration market’s growth. Market Driver for Macular Edema and Macular Degeneration: Higher Occurrence of Eye Disorders Stimulates Market Growth

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Are the Key Market Segments in the Macular Edema and Macular Degeneration Industry?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

What Are the Latest Trends in the Macular Edema and Macular Degeneration Market?

To boost their profitability within the macular edema and macular degeneration market, key players are spearheading the development of innovative products such as Vabysmo (faricimab-svoa). This medication is primarily used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In a significant instance, Genentech Inc., an American biotechnology firm, obtained FDA approval for Vabysmo (faricimab-svoa) in January 2022. It’s a bispecific antibody aiming at vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), marking its position as the first bispecific monoclonal antibody targeting both conditions. Faricimab carries the potential of becoming a best-selling drug for the treatment of nAMD and DME. Its approval from the FDA and EU is counted as a crucial achievement for both Genentech and Roche.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Are the Key Regional Markets in the Macular Edema and Macular Degeneration Industry?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

This Report Delivers Insight On:

1. How big is the macular edema and macular degeneration market, and how is it changing globally?

2. Who are the major companies in the macular edema and macular degeneration market, and how are they performing?

3. What are the key opportunities and risks in the macular edema and macular degeneration market right now?

4. Which products or customer segments are growing the most in the macular edema and macular degeneration market?

5. What factors are helping or slowing down the growth of the macular edema and macular degeneration market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model